Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Insulin and IGF-1 receptors regulate complex I–dependent mitochondrial bioenergetics and supercomplexes via FoxOs in muscle
Gourav Bhardwaj, … , E. Dale Abel, Brian T. O’Neill
Gourav Bhardwaj, … , E. Dale Abel, Brian T. O’Neill
Published August 3, 2021
Citation Information: J Clin Invest. 2021;131(18):e146415. https://doi.org/10.1172/JCI146415.
View: Text | PDF
Research Article Endocrinology

Insulin and IGF-1 receptors regulate complex I–dependent mitochondrial bioenergetics and supercomplexes via FoxOs in muscle

  • Text
  • PDF
Abstract

Decreased skeletal muscle strength and mitochondrial dysfunction are characteristic of diabetes. The actions of insulin and IGF-1 through the insulin receptor (IR) and IGF-1 receptor (IGF1R) maintain muscle mass via suppression of forkhead box O (FoxO) transcription factors, but whether FoxO activation coordinates atrophy in concert with mitochondrial dysfunction is unknown. We show that mitochondrial respiration and complex I activity were decreased in streptozotocin (STZ) diabetic muscle, but these defects were reversed in muscle-specific FoxO1, -3, and -4 triple-KO (M-FoxO TKO) mice rendered diabetic with STZ. In the absence of systemic glucose or lipid abnormalities, muscle-specific IR KO (M-IR–/–) or combined IR/IGF1R KO (MIGIRKO) impaired mitochondrial respiration, decreased ATP production, and increased ROS. These mitochondrial abnormalities were not present in muscle-specific IR, IGF1R, and FoxO1, -3, and -4 quintuple-KO mice (M-QKO). Acute tamoxifen-inducible deletion of IR and IGF1R also decreased muscle pyruvate respiration, complex I activity, and supercomplex assembly. Although autophagy was increased when IR and IGF1R were deleted in muscle, mitophagy was not increased. Mechanistically, RNA-Seq revealed that complex I core subunits were decreased in STZ-diabetic and MIGIRKO muscle, and these changes were not present with FoxO KO in STZ-FoxO TKO and M-QKO mice. Thus, insulin-deficient diabetes or loss of insulin/IGF-1 action in muscle decreases complex I–driven mitochondrial respiration and supercomplex assembly in part by FoxO-mediated repression of complex I subunit expression.

Authors

Gourav Bhardwaj, Christie M. Penniman, Jayashree Jena, Pablo A. Suarez Beltran, Collin Foster, Kennedy Poro, Taylor L. Junck, Antentor O. Hinton Jr., Rhonda Souvenir, Jordan D. Fuqua, Pablo E. Morales, Roberto Bravo-Sagua, William I. Sivitz, Vitor A. Lira, E. Dale Abel, Brian T. O’Neill

×

Figure 5

Tamoxifen-inducible deletion of IR and IGF1R in muscle decreases muscle strength, soleus fiber respiration, ATP production, complex I activity, OXPHOS proteins, and mitochondrial area density.

Options: View larger image (or click on image) Download as PowerPoint
Tamoxifen-inducible deletion of IR and IGF1R in muscle decreases muscle ...
(A) mRNA levels of IR and IGF1R in soleus muscle 3 weeks after a 5-day course of tamoxifen treatment in IND-IGIRKO and IR/IGF1Rfl/fl mice. (B and C) Western blot (B) and densitometry (C) of IR and IGF1R in soleus from IND IGIRKO. (D) Soleus muscle weight in IND-IGIRKO and IR/IGF1Rfl/fl mice (n = 5–6). (E and F) Forelimb grip strength (E), treadmill run time (F), and speed at the time of exhaustion (G) in IND-IGIRKO and IR/IGF1Rfl/fl (n = 7). (H) Respiratory capacity in permeabilized soleus fibers with PYR/M, then subsequent addition of ADP, succinate, rotenone, oligomycin, and FCCP in IND-IGIRKO and IR/IGF1Rfl/fl (n = 10–12). (I) ATP generation in soleus fibers with PYR/M from IND-IGIRKO (n = 5-6). (J–L) OXPHOS complex I in quad (J) and complex II (K) and complex III (L) activity in gast from IND-IGIRKO and IR/IGF1Rfl/fl (n = 6). (M–P) Western blot (M) with densitometry of OXPHOS proteins (N), Ndufs1 (O), and Vdac (P) in quad from IND-IGIRKO and IR/IGF1Rfl/fl (n = 13 for OXPHOS and Ndufs1; n = 6 for Vdac). (Q and R) Electron micrographs (I) and quantitation of mitochondrial area density (J) in soleus from IND-IGIRKO and IR/IGF1Rfl/fl (n = 5–6). Results are represented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 vs. littermate control, t test for 2 groups. ponS, PonceauS for normalization.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts